Averitas Pharma Inc.
$3.5M 14,332 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. reported $3,452,616.16 across General Payments, Research, and Ownership to 5,232 physicians and teaching hospitals across 5,459 transactions.
- $3.5M Top quartile payer
- All-tracks total
- 5,459 Top quartile volume
- Transactions
- 5,232 Top quartile reach
- Recipients
- −$288.1K
- General Payments vs PY2023
Puma Biotechnology, Inc. reported $3,452,616.16 across all CMS Open Payments tracks (General + Research + Ownership) to 5,232 physicians and teaching hospitals in Program Year 2024 - ranking #333 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $396,836.67, averaging $659.90 per recipient.
How Puma Biotechnology, Inc.'s $3.5M all-tracks total breaks down
Puma Biotechnology, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
51/100
Total payments
F
42/100
Transaction volume
D
50/100
Physician reach
D
50/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer puma-biotechnology-inc Puma Biotechnology, Inc.
$3.5M · #333/1,925 · 0.0% industry · PY2024
- TOT $3.5M
- RANK #333
- SHARE 0.0%
- TXN 5,459
- RCP 5,232
- CAT 5
- GEN $396.8K
- ΔGEN −$288.1K
- TOP1 40.2%
- PY 2024
Volume peers
Nearest volume peer: Averitas Pharma Inc. ($3.5M)
Puma Biotechnology, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Puma Biotechnology, Inc.'s CMS-reported General Payments decreased by $288.1K (−42.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PUMA BIOTECHNOLOGY, INC.PY2023: PUMA BIOTECHNOLOGY, INC.PY2024: PUMA BIOTECHNOLOGY, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $684,967.83
- PY2024
- $396,836.67
What the Data Shows for Puma Biotechnology, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Puma Biotechnology, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
17 transactions worth $191.2K make "Consulting Fee" the top general-payment category in the 5-category breakdown below, 48.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Puma Biotechnology, Inc. made 5 types of general payments. "Consulting Fee" is the largest category at $191.2K, 48.2% of General Payments.
Puma Biotechnology, Inc. reports 5 general-payment categories - the top three are Consulting Fee (48.2%), Food and Beverage (28.5%), and Compensation for Services Other Than Consulting (11.2%). The remaining 2 categories make up 12.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Puma Biotechnology, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $191.2K | 17 | 48.2% |
| Food and Beverage | $113.1K | 5,166 | 28.5% |
| Compensation for Services Other Than Consulting | $44.6K | 9 | 11.2% |
| Space Rental or Facility Fees | $39.9K | 16 | 10.1% |
| Travel and Lodging | $8.0K | 24 | 2.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $224,650.09 (56.6%) of $396,836.67 in this company's General Payments records across 3,223 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Puma Biotechnology, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Adrian M Senderowicz
$159,640.00 across 5 reported transactions
- 2
Anne P. O'dea
$34,881.34 across 18 reported transactions
- 3
Vijayakrishna K Gadi
$10,883.75 across 10 reported transactions
- 4
Scripps Mercy Hospital
$10,500.00 across 3 reported transactions
- 5
Mayo Clinic Hospital
$8,745.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Puma Biotechnology, Inc. ranks #333 of 1,925 by total payments (top 17% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #808 of 1,838 by HHI (top 44% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- NextStep Arthropedix, LLC : $125.7K total payments, HHI 1747
- Greiner Bio-One North America, Inc. : $11.6K total payments, HHI 1746
- CashFlow Solutions, LLC : $89.2K total payments, HHI 1745
- Acumed LLC : $3.4M total payments, HHI 1742
- Thermo Fisher Scientific Asheville LLC : $2.2K total payments, HHI 1739
- Albireo Pharma, Inc. : $317.2K total payments, HHI 1739
- Puma Biotechnology, Inc. (this company) : $396.8K total payments, HHI 1733
- Pulse Biosciences, Inc. : $534.8K total payments, HHI 1730
- SS White Burs, Inc. : $65.6K total payments, HHI 1718
- Maquet Cardiovascular L.L.C. : $188.3K total payments, HHI 1714
- GS Solutions, Inc. : $38.7K total payments, HHI 1706
- Mitsubishi Tanabe Pharma Corporation : $92.7K total payments, HHI 1705
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Puma Biotechnology, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Puma Biotechnology, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Puma Biotechnology, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Sumitomo Pharma Co., Ltd.
$3.5M 89 recipients
Compare payment profiles
Acumed LLC
$3.5M 4,053 recipients
Compare payment profiles
Integra LifeSciences Corporation
$3.4M 18,727 recipients
Compare payment profiles
Amplify Surgical, Inc.
$3.5M 66 recipients
Compare payment profiles
Kowa Company, Ltd.
$3.5M 0 recipients
Compare payment profiles
Put this to use
Puma Biotechnology, Inc. ranks #333 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Puma Biotechnology, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Puma Biotechnology, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.